Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma cell disorder characterised by a serum M protein level below 3 g/dL, percentage of bone marrow clonal plasma cells below 10%, absence of end-organ damage (hypercalcaemia, renal insufficiency, anaemia, bone lesions) and absence of any other disease known to produce M protein. MGUS may progress to myeloproliferative disorders or multiple myeloma, but very little is known about any modifiable risk factors or any preventative treatment that might delay this progression. Metformin has begun to be discussed as a potentially useful agent on the basis of the results of epidemiological and preclinical research showing that it may be beneficial in patients with leukaemia, lymphomas and multiple myeloma. Metformin studies dedicated to MGUS are currently very limited, yet it would appear that there may be hope for reducing progression of MGUS to multiple myeloma with metformin in type 2 diabetes mellitus. However, more data is needed until we reach a clearer view of what is to be gained with metformin in this setting.
Avoid common mistakes on your manuscript.
Monoclonal gammopathy of undetermined significance is an asymptomatic plasma cell disorder characterised by a serum M protein level below 3 g/dL, percentage of bone marrow clonal plasma cells below 10%, absence of end-organ damage and absence of any other disease known to produce M protein |
Monoclonal gammopathy of undetermined significance may progress to myeloproliferative disorders or multiple myeloma, but very little is known about any modifiable risk factors or any preventative treatment that might delay this progression |
Metformin has begun to be discussed as a potentially useful agent in monoclonal gammopathy of undetermined significance as it has been demonstrated that it may be beneficial in patients with leukaemia, lymphomas and multiple myeloma |
Although dedicated studies are currently very limited, it would appear that there may be hope for reducing progression of monoclonal gammopathy of undetermined significance to multiple myeloma with metformin in type 2 diabetes mellitus |
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma cell disorder characterised by a serum M protein level below 3 g/dL, percentage of bone marrow clonal plasma cells below 10%, absence of end-organ damage (hypercalcaemia, renal insufficiency, anaemia, bone lesions) and absence of any other disease known to produce M protein [1]. MGUS is encountered in 1.11% of Chinese, 3.2% of Caucasian and 3.7% of African-American adults at least 50 years old and may progress to myeloproliferative disorders or multiple myeloma [1, 2]. Importantly, very little is known about any modifiable risk factors or any preventative treatment that might delay progression [2, 3].
In this context, metformin has begun to be discussed as a potentially useful agent. Its postulated actions may be manifold. Indeed, on the basis of epidemiological and preclinical research, this agent may be beneficial in patients with leukaemia, lymphomas and multiple myeloma [4, 5]. Metformin might reduce pro-inflammatory soluble mediators (e.g. interleukin-6 and insulin-like growth factor 1 (IGF1) [6]. Moreover, it may improve T cell and immune suppressor cell function, increasing anti-tumour activity [7]. Of note, reduction of insulin and IGF1 production with increased insulin sensitivity due to metformin are considered to reduce progression of MGUS to multiple myeloma [8, 9]. Finally, metformin activates the adenosine monophosphate-activated protein kinase signalling pathway, which induces apoptosis of myeloma cells and contributes to suppression of bone resorption [10].
Metformin studies dedicated to MGUS are currently very limited. We performed an electronic search in PubMed, Google Scholar and SCOPUS databases until February 2022 using combinations of the following keywords: MGUS; metformin; monoclonal gammopathy of undetermined significance; multiple myeloma; progression; type 2 diabetes mellitus. Only publications in English were considered.
Chang et al. [11] retrospectively studied 3287 US veterans with MGUS and type 2 diabetes mellitus (T2DM). Metformin users exhibited a lower risk of progression to multiple myeloma than non-users. In their sensitivity analyses, in which they explored metformin use 2–6 years after T2DM diagnosis, the following hazard ratio (HR) and 95% confidence interval (CI) were identified, depending on years of metformin therapy: HR 0.76, 95% CI 0.48–1.12 for 2-year use; HR 0.63, 95% CI 0.38–1.05 for 3-year use; HR 0.50, 95% CI 0.23–1.06 for 5-year use; HR 0.58, 95% CI 0.24–1.40 for 6-year use [11]. In metformin users, significantly reduced incidence of multiple myeloma (3% vs. 5%) and significantly increased median time of progression to multiple myeloma (71 vs. 47 months) were seen [11].
Two case–control studies have looked at the utility of metformin [12, 13]. Boursi et al. [12] identified 124 MGUS cases progressing to multiple myeloma. Subjects with T2DM but without antidiabetic therapy exhibited no increased risk of developing multiple myeloma (odds ratio [OR] 0.96, 95% CI 0.38–2.38). In contrast, metformin-treated subjects with T2DM had a non-significant reduction of this risk (OR 0.39, 95% CI 0.14–1.13) [12]. The same held true for other antidiabetic agents (sulfonylureas, thiazolidinediones and insulin) without metformin (OR 0.17, 95% CI 0.02–1.28). Thus, metformin appeared protective, but wide confidence intervals precluded significance and this applied also to other antidiabetic agents [12]. Similarly, another study of 2363 patients with MGUS and 9193 controls showed a borderline significant reduction (OR 0.77, 95% CI 0.56–1.05) in the risk of progression to multiple myeloma among metformin-treated subjects with T2DM vs. those without diabetes [13].
It would appear that there may be hope for reducing progression of MGUS to multiple myeloma with metformin in T2DM. This prospect is nowadays beginning to be discussed more vividly [14]. However, more data is needed, until we reach a clearer view of what is to be gained with metformin in this setting. Interestingly, a phase 2, double-blind, randomised placebo-controlled trial is now being carried out (NCT04850846) [15]. It is recruiting patients with higher-risk MGUS and low-risk smouldering multiple myeloma not previously diagnosed with diabetes mellitus, aiming to investigate the efficacy of metformin in reducing clinical indicators of disease progression [15]. Studies with enough cases and adequate follow-up will be required, so as to ascertain whether any such protective effect of metformin in T2DM is consistent and significant. We will also need to look at the effect of tight glycaemic control per se, as well as at any patient characteristics that might increase the protection offered by metformin. A better understanding of underlying mechanisms will be appreciated as well.
In conclusion, it is being discussed that metformin may contribute to reduced progression of MGUS to multiple myeloma in subjects with T2DM. However, data is very limited for the moment and we need to know a lot more before we reach a definitive answer. Should this beneficial effect be confirmed, it would enrich the widespread appreciation of this agent’s variegated pleiotropic actions, from anti-tumour [5, 16] to anti-depressive [17].
This article is based on previously conducted studies and does not contain any novel data from studies with human participants or animals performed by any of the authors.
References
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
Han JH, Wang JN, Zhang YL, et al. Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China. Blood Cancer J. 2020;10:34.
Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338–45.
Liu X, Zhao Y, Zhang E, Yan H, Lv N, Cai Z. The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3. Biochem Biophys Res Commun. 2019;515:332–8.
Podhorecka M. Metformin – its anti-cancer effects in hematologic malignancies. Oncol Rev. 2021;15:514.
Mishra AK, Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia. 2019;33:2695–709.
Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GV, Oyajobi BO. PKA/AMPK signaling in relation to adiponectin’s antiproliferative effect on multiple myeloma cells. Leukemia. 2014;28:2080–9.
Birman BM, Neuhouser ML, Rosner B, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012;120:4929–37.
Verdura S, Cuyas E, Martin-Castillo B, Menendez JA. Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. Oncoimmunology. 2019;8:e1633235.
Lee YS, Kim YS, Lee SY, et al. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone. 2010;47:926–37.
Chang SH, Luo S, O’Brian KK, et al. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematol. 2015;2:e30–6.
Boursi B, Mamtani R, Yang YX, Weiss BM. Impact of metformin on the progression of MGUS to multiple myeloma. Leuk Lymphoma. 2016;58:1265–7.
Boursi B, Weiss BM, Haynes K, Mamtani R, Yang YX. Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. Am J Hematol. 2016;91:581–4.
da Cunha Júnior AD, Zanette DL, Pericole FV, Olalla Saad ST, Barreto Campello Carvalheira J. Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment? Adv Hematol. 2021;2021:6615684.
https://clinicaltrials.gov/ct2/show/NCT04850846. Last accessed 27 Feb 2022.
Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs. 2010;19:913–7.
Papachristou S, Papanas N. Reduction of depression in diabetes: a new pleiotropic action of metformin? Diabetes Ther. 2021;12:965–8.
Acknowledgements
Funding
No funding or sponsorship was received for this study or publication of this article.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Author Contributions
Stella Papachristou analysed the literature and wrote the manuscript; Djordje S. Popovic reviewed and edited the manuscript; Nikolaos Papanas reviewed, edited and finalised the manuscript.
Disclosures
This manuscript was written independently and the authors did not receive financial or professional help for its preparation. Stella Papachristou declares no potential conflicts of interest. Djordje S. Popovic declares associations with: Abbott, Alkaloid, AstraZeneca, Boehringer-Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, and Worwag Pharma. Nikolaos Papanas has been an advisory board member of TrigoCare International, Abbott, AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi-Aventis, and Takeda; has participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis, and Sanofi-Aventis; received honoraria as a speaker for AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Elpen, Galenica, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda, and Vianex; and attended conferences sponsored by TrigoCare International, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer, and Sanofi-Aventis. None of the aforementioned companies had any role in this article, which has been written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.
Compliance with ethics guidelines
This article is based on previously conducted studies and does not contain any novel data from studies with human participants or animals performed by any of the authors.
Data availability
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papachristou, S., Popovic, D.S. & Papanas, N. Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?. Adv Ther 39, 2283–2286 (2022). https://doi.org/10.1007/s12325-022-02125-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-022-02125-1